Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties

J. S. Day, M. Ding, P. Bednarz, J. C. van der Linden, T. Mashiba, T. Hirano, C. C. Johnston, David Burr, I. Hvid, D. R. Sumner, H. Weinans

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Bisphosphonates are emerging as an important treatment for osteoporosis. But whether the reduced fracture risk associated with bisphosphonate treatment is due to increased bone mass, improved trabecular architecture and/or increased secondary mineralization of the calcified matrix remains unclear. We examined the effects of bisphosphonates on both the trabecular architecture and matrix properties of canine trabecular bone. Thirty-six beagles were divided into a control group and two treatment groups, one receiving risedronate and the other alendronate at 5-6 times the clinical dose for osteoporosis treatment. After one year, the dogs were killed, and samples from the first lumbar vertebrae were examined using a combination of micro-computed tomography, finite element modeling, and mechanical testing. By combining these methods, we examined the treatment effects on the calcified matrix and trabecular architecture independently. Conventional histomorphometry and microdamage data were obtained from the second and third lumbar vertebrae of the same dogs [Bone 28 (2001) 524]. Bisphosphonate treatment resulted in an increased apparent Young's modulus, decreased bone turnover, increased calcified matrix density, and increased microdamage. We could not detect any change in the effective Young's modulus of the calcified matrix in the bisphosphonate treated groups. The observed increase in apparent Young's modulus was due to increased bone mass and altered trabecular architecture rather than changes in the calcified matrix modulus. We hypothesize that the expected increase in the Young's modulus of the calcified matrix due to the increased calcified matrix density was counteracted by the accumulation of microdamage.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalJournal of Orthopaedic Research
Volume22
Issue number3
DOIs
StatePublished - 2004

Fingerprint

Diphosphonates
Elastic Modulus
Lumbar Vertebrae
Bone and Bones
Osteoporosis
Dogs
Alendronate
Bone Remodeling
Canidae
Tomography
Cancellous Bone
Control Groups

Keywords

  • Bisphosphonates
  • Bone matrix mineralization
  • Bone micro-architecture
  • Mechanical properties
  • Osteoporosis

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. / Day, J. S.; Ding, M.; Bednarz, P.; van der Linden, J. C.; Mashiba, T.; Hirano, T.; Johnston, C. C.; Burr, David; Hvid, I.; Sumner, D. R.; Weinans, H.

In: Journal of Orthopaedic Research, Vol. 22, No. 3, 2004, p. 465-471.

Research output: Contribution to journalArticle

Day, JS, Ding, M, Bednarz, P, van der Linden, JC, Mashiba, T, Hirano, T, Johnston, CC, Burr, D, Hvid, I, Sumner, DR & Weinans, H 2004, 'Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties', Journal of Orthopaedic Research, vol. 22, no. 3, pp. 465-471. https://doi.org/10.1016/j.orthres.2003.05.001
Day, J. S. ; Ding, M. ; Bednarz, P. ; van der Linden, J. C. ; Mashiba, T. ; Hirano, T. ; Johnston, C. C. ; Burr, David ; Hvid, I. ; Sumner, D. R. ; Weinans, H. / Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. In: Journal of Orthopaedic Research. 2004 ; Vol. 22, No. 3. pp. 465-471.
@article{26444b53bfb94c969a7bf5c3af5f6f46,
title = "Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties",
abstract = "Bisphosphonates are emerging as an important treatment for osteoporosis. But whether the reduced fracture risk associated with bisphosphonate treatment is due to increased bone mass, improved trabecular architecture and/or increased secondary mineralization of the calcified matrix remains unclear. We examined the effects of bisphosphonates on both the trabecular architecture and matrix properties of canine trabecular bone. Thirty-six beagles were divided into a control group and two treatment groups, one receiving risedronate and the other alendronate at 5-6 times the clinical dose for osteoporosis treatment. After one year, the dogs were killed, and samples from the first lumbar vertebrae were examined using a combination of micro-computed tomography, finite element modeling, and mechanical testing. By combining these methods, we examined the treatment effects on the calcified matrix and trabecular architecture independently. Conventional histomorphometry and microdamage data were obtained from the second and third lumbar vertebrae of the same dogs [Bone 28 (2001) 524]. Bisphosphonate treatment resulted in an increased apparent Young's modulus, decreased bone turnover, increased calcified matrix density, and increased microdamage. We could not detect any change in the effective Young's modulus of the calcified matrix in the bisphosphonate treated groups. The observed increase in apparent Young's modulus was due to increased bone mass and altered trabecular architecture rather than changes in the calcified matrix modulus. We hypothesize that the expected increase in the Young's modulus of the calcified matrix due to the increased calcified matrix density was counteracted by the accumulation of microdamage.",
keywords = "Bisphosphonates, Bone matrix mineralization, Bone micro-architecture, Mechanical properties, Osteoporosis",
author = "Day, {J. S.} and M. Ding and P. Bednarz and {van der Linden}, {J. C.} and T. Mashiba and T. Hirano and Johnston, {C. C.} and David Burr and I. Hvid and Sumner, {D. R.} and H. Weinans",
year = "2004",
doi = "10.1016/j.orthres.2003.05.001",
language = "English",
volume = "22",
pages = "465--471",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties

AU - Day, J. S.

AU - Ding, M.

AU - Bednarz, P.

AU - van der Linden, J. C.

AU - Mashiba, T.

AU - Hirano, T.

AU - Johnston, C. C.

AU - Burr, David

AU - Hvid, I.

AU - Sumner, D. R.

AU - Weinans, H.

PY - 2004

Y1 - 2004

N2 - Bisphosphonates are emerging as an important treatment for osteoporosis. But whether the reduced fracture risk associated with bisphosphonate treatment is due to increased bone mass, improved trabecular architecture and/or increased secondary mineralization of the calcified matrix remains unclear. We examined the effects of bisphosphonates on both the trabecular architecture and matrix properties of canine trabecular bone. Thirty-six beagles were divided into a control group and two treatment groups, one receiving risedronate and the other alendronate at 5-6 times the clinical dose for osteoporosis treatment. After one year, the dogs were killed, and samples from the first lumbar vertebrae were examined using a combination of micro-computed tomography, finite element modeling, and mechanical testing. By combining these methods, we examined the treatment effects on the calcified matrix and trabecular architecture independently. Conventional histomorphometry and microdamage data were obtained from the second and third lumbar vertebrae of the same dogs [Bone 28 (2001) 524]. Bisphosphonate treatment resulted in an increased apparent Young's modulus, decreased bone turnover, increased calcified matrix density, and increased microdamage. We could not detect any change in the effective Young's modulus of the calcified matrix in the bisphosphonate treated groups. The observed increase in apparent Young's modulus was due to increased bone mass and altered trabecular architecture rather than changes in the calcified matrix modulus. We hypothesize that the expected increase in the Young's modulus of the calcified matrix due to the increased calcified matrix density was counteracted by the accumulation of microdamage.

AB - Bisphosphonates are emerging as an important treatment for osteoporosis. But whether the reduced fracture risk associated with bisphosphonate treatment is due to increased bone mass, improved trabecular architecture and/or increased secondary mineralization of the calcified matrix remains unclear. We examined the effects of bisphosphonates on both the trabecular architecture and matrix properties of canine trabecular bone. Thirty-six beagles were divided into a control group and two treatment groups, one receiving risedronate and the other alendronate at 5-6 times the clinical dose for osteoporosis treatment. After one year, the dogs were killed, and samples from the first lumbar vertebrae were examined using a combination of micro-computed tomography, finite element modeling, and mechanical testing. By combining these methods, we examined the treatment effects on the calcified matrix and trabecular architecture independently. Conventional histomorphometry and microdamage data were obtained from the second and third lumbar vertebrae of the same dogs [Bone 28 (2001) 524]. Bisphosphonate treatment resulted in an increased apparent Young's modulus, decreased bone turnover, increased calcified matrix density, and increased microdamage. We could not detect any change in the effective Young's modulus of the calcified matrix in the bisphosphonate treated groups. The observed increase in apparent Young's modulus was due to increased bone mass and altered trabecular architecture rather than changes in the calcified matrix modulus. We hypothesize that the expected increase in the Young's modulus of the calcified matrix due to the increased calcified matrix density was counteracted by the accumulation of microdamage.

KW - Bisphosphonates

KW - Bone matrix mineralization

KW - Bone micro-architecture

KW - Mechanical properties

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=11144353705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144353705&partnerID=8YFLogxK

U2 - 10.1016/j.orthres.2003.05.001

DO - 10.1016/j.orthres.2003.05.001

M3 - Article

C2 - 15099622

AN - SCOPUS:11144353705

VL - 22

SP - 465

EP - 471

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 3

ER -